128 related articles for article (PubMed ID: 8738813)
1. Effects of recombinant human erythropoietin on porphyrin metabolism in uremic patients on hemodialysis.
Fontanellas A; Herrero JA; Coronel F; Santos JL; Morán MJ; Barrientos A; Enríquez de Salamanca R
J Am Soc Nephrol; 1996 May; 7(5):774-9. PubMed ID: 8738813
[TBL] [Abstract][Full Text] [Related]
2. Heme biosynthesis in uremic patients on CAPD or hemodialysis.
Fontanellas A; Coronel F; Santos JL; Herrero JA; Moran MJ; Guerra P; Tornero F; de Salamanca RE
Kidney Int; 1994 Jan; 45(1):220-3. PubMed ID: 8127011
[TBL] [Abstract][Full Text] [Related]
3. Heme synthesis in chronic renal failure: the effects of hemodialysis, peritoneal dialysis and erythropoietin treatment.
Siersema PD; de Rooij FW; Edixhoven-Bosdijk A; Weimar W; Wilson JH
Nephron; 1995; 71(3):297-302. PubMed ID: 8569978
[TBL] [Abstract][Full Text] [Related]
4. Heme synthesis in anemia of the uremic state.
Linkesch W; Stummvoll HK; Wolf A; Müller M
Isr J Med Sci; 1978 Nov; 14(11):1173-6. PubMed ID: 750546
[TBL] [Abstract][Full Text] [Related]
5. Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients.
Guolo M; Stella AM; Melito V; Parera V; Del C Batlle AM
Int J Biochem Cell Biol; 1996 Mar; 28(3):311-7. PubMed ID: 8920640
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities of heme biosynthesis in experimental acute renal failure.
Fontanellas A; Herrero JA; Trobo JI; Morán MJ; Coronel F; Barrientos A; de Salamanca RE
J Am Soc Nephrol; 1996 Apr; 7(4):628-32. PubMed ID: 8724898
[TBL] [Abstract][Full Text] [Related]
7. Effect of aluminum on porphyrin metabolism in hemodialyzed patients.
Buchet JP; Lauwerys R; Hassoun A; Dratwa M; Wens R; Collart F; Tielemans C
Nephron; 1987; 46(4):360-3. PubMed ID: 3658064
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis.
Piazza V; Villa G; Galli F; Segagni S; Bovio G; Poggio F; Picardi L; Salvadeo A
Nephron; 1992; 61(1):54-7. PubMed ID: 1528341
[TBL] [Abstract][Full Text] [Related]
9. Effect of human recombinant erythropoietin treatment on erythrocyte delta-aminolevulinic acid dehydratase in patients on maintenance hemodialysis.
Djordjević VB; Pavlović D; Pejović M; Lecić N; Koraćević D; Djordjević V; Stefanović V
Nephron; 1993; 65(3):497-8. PubMed ID: 8290015
[No Abstract] [Full Text] [Related]
10. The regulation of heme biosynthesis during erythropoietin-induced erythroid differentiation.
Beru N; Goldwasser E
J Biol Chem; 1985 Aug; 260(16):9251-7. PubMed ID: 4019471
[TBL] [Abstract][Full Text] [Related]
11. Treatment of the anemia of hemodialysis patients with recombinant human erythropoietin.
Schaefer RM; Kuerner B; Zech M; Denninger G; Borneff C; Heidland A
Int J Artif Organs; 1988 Jul; 11(4):249-54. PubMed ID: 3410565
[TBL] [Abstract][Full Text] [Related]
12. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
[TBL] [Abstract][Full Text] [Related]
13. Reduced aminolevulinic dehydrase activity with increased blood porphyrins in experimental chronic renal failure.
Fontanellas A; Torralbo A; Santos JL; Morán MJ; Barrientos A; Enríquez de Salamanca R
Exp Nephrol; 1997; 5(1):95-9. PubMed ID: 9052854
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of erythrocyte aminolevulinate dehydratase by a 56.2-kD peptide from uremic plasma.
Guolo M; Machalinski C; Biscoglio M; Stella AM; Franco C; Pataro L; de Salamanca RE; Batlle A
Exp Nephrol; 1999; 7(3):236-41. PubMed ID: 10352364
[TBL] [Abstract][Full Text] [Related]
15. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
16. Levels of delta-aminolevulinate dehydratase, uroporphyrinogen-I synthase, and protoporphyrin IX in erythrocytes from anemic mutant mice.
Sassa S; Bernstein SE
Proc Natl Acad Sci U S A; 1977 Mar; 74(3):1181-4. PubMed ID: 265562
[TBL] [Abstract][Full Text] [Related]
17. Effect of recombinant human erythropoietin (r-HuEPO) therapy on plasma FT3, FT4, TSH, FSH, LH, free testosterone and prolactin levels in hemodialysis patients.
Yeksan M; Tamer N; Cirit M; Türk S; Akhan G; Akkus I; Erkul I
Int J Artif Organs; 1992 Oct; 15(10):585-9. PubMed ID: 1428205
[TBL] [Abstract][Full Text] [Related]
18. Increased erythrocyte uroporphyrinogen-l-synthetase, delta-aminolevulinic acid dehydratase and protoporphyrin in hemolytic anemias.
Anderson KE; Sassa S; Peterson CM; Kappas A
Am J Med; 1977 Sep; 63(3):359-64. PubMed ID: 900140
[No Abstract] [Full Text] [Related]
19. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin].
Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA
Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
